Medinol Strikes Twice: Guidant Entanglement May Affect Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Medinol is seeking royalties of at least 20% from past and future sales of Guidant's Multi-Link stent platform in an upcoming patent infringement trial that could begin by April